LAB — Standard BioTools Share News
0.000.00%
Last trade - 00:00- $258.47m
- -$217.95m
- $85.33m
Brief: Standard Biotools Provides Update On Sale Of Mass Cytometry Business
Standard BioTools Inc. reports results for the quarter ended June 30 - Earnings Summary
Standard BioTools Q2 revenue falls on consumables weakness
Brief: Standard BioTools Q2 EPS USD -0.07
Standard BioTools Inc. expected to post a loss of 1 cent a share - Earnings Preview
Brief: Standard Biotools - Enters Termination, Waiver And Release Agreement With Illumina On July 24, 2026 - SEC Filing
Brief: Standard Biotools Announces Sale Of Mass Cytometry Business And Illumina’S Buyout Of Contingent Payments To Advance Merger With Treeline Biosciences
NASDAQ RESUMED AT 08:00 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM
Brief: Standard Biotools - Approves 2026 Change Of Control And Severance Plan On May 21, 2026
Standard BioTools Q1 adjusted EBITDA loss narrows
Brief: Standard BioTools Q1 EPS USD 0.33
Standard BioTools Q4 EBITDA misses estimates
Standard BioTools Q3 revenue falls
Brief: Standard BioTools Q3 EPS USD -0.09
Brief: Standard Biotools Announces 15% Global Workforce Reduction - SEC Filing
Brief: Illumina® Protein Prep Launches To Drive Greater Proteomic Insights For Improved Drug Discovery And Development
Brief: Illumina® Protein Prep Launches To Drive Greater Proteomic Insights For Improved Drug Discovery And Development
Standard BioTools Inc reports results for the quarter ended June 30 - Earnings Summary